Glaxo's In-Licensing Binge Continues
Executive Summary
The message of GSK's recent $270 million dollar licensing deal with Adolor is that, so long as Big Pharma pipelines are suffering and patents keep expiring, late-stage products from small companies can command highly respectable prices. And GSK’s active dealmaking shows that this company, unlike many of its competitors, recognizes that late-stage products still carry enormous risk.